Condition: Non-small Cell Lung Cancer (NSCLC) · Sponsor: Nuvation Bio Inc.
The purpose of this phase 3 multicenter double-blind randomized study is to assess the use of taletrectinib in the early-stage non-small cell lung cancer (NSCLC). The study compares taletrectinib (study drug) versus placebo (sugar pill) in patients with ROS1-fusion positive stage IB, II, IIIA NSCLC. The study will evaluate if taletrectinib is better than placebo at preventing the participant's disease from coming back after the participant's lung tumor was removed.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| UCLA | Los Angeles, California, United States | Recruiting |
| UCI Chao Family Comprehensive Cancer Center | Orange, California, United States | Recruiting |
| Georgetown University Medical Cener (GUMC) | Washington D.C., District of Columbia, United States | Recruiting |
| Advent Health | Orlando, Florida, United States | Recruiting |
| Saint Alphonsus Health System | Boise, Idaho, United States | Recruiting |
| Tulane Cancer Center | New Orleans, Louisiana, United States | Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Sarah Cannon Research Institute (SCRI) - Texas Oncology-Central South | Austin, Texas, United States | Recruiting |
| MD Anderson | Houston, Texas, United States | Recruiting |
| Virginia Cancer Specialists | Fairfax, Virginia, United States | Recruiting |
+ 21 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07154706